ResearcherAzienda Unità Sanitaria Locale PiacenzaActive in the last 2 years
Stefano Vecchia
Matched on ORCID iD 0000-0003-0578-0870; OpenAlex author ID A5059720509. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper
Papers 7
- Polypharmacy in Elderly Patients Receiving First-Line Treatment for Pancreatic Adenocarcinoma: Analysis of Potential Drug-Drug Interactions and Outcome. Co-author DOI 10.32604/or.2026.076944↗
- Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. First author DOI 10.3390/cancers17050747↗
- State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. Co-author DOI 10.3390/ijms26062620↗
- Comparing Combination vs Monochemotherapy in Late-Elderly Patients With Advanced Pancreatic Cancer: Insights From a Single-Center Study. Last author DOI 10.1177/10732748241304968↗
- FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. Last author DOI 10.21873/cdp.10303↗
- Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression-A Scoping… Co-author DOI 10.3390/cancers16162912↗
- Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single cente… Last author DOI 10.2147/ott.s200754↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elena Orlandi · 7 shared papers, 2019–2026 · strength 1.67
- Paper Polypharmacy in Elderly Patients Receiving First-Line Treatment for Pancreatic Adenocarcinoma: Analysis of Potential Dr… DOI 10.32604/or.2026.076944↗
- Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
- Paper Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. DOI 10.3390/cancers17050747↗
- Chiara Citterio · 6 shared papers, 2019–2026 · strength 1.46
- Paper Polypharmacy in Elderly Patients Receiving First-Line Treatment for Pancreatic Adenocarcinoma: Analysis of Potential Dr… DOI 10.32604/or.2026.076944↗
- Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
- Paper Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. DOI 10.3390/cancers17050747↗
- Mario Giuffrida · 3 shared papers, 2024–2025 · strength 0.72
- Paper Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. DOI 10.3390/cancers17050747↗
- Paper State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. DOI 10.3390/ijms26062620↗
- Paper Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Gro… DOI 10.3390/cancers16162912↗
- Andrea Romboli · 2 shared papers, 2024–2025 · strength 0.46
- Paper State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. DOI 10.3390/ijms26062620↗
- Paper Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Gro… DOI 10.3390/cancers16162912↗
- Luigi Cavanna MD · 2 shared papers, 2019–2024 · strength 0.38
- Filippo Banchini Banchini · 1 shared paper, 2025 · strength 0.26
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.